In the News

Major progress has been made in the gastrointestinal (GI) therapeutic areas of gastroesophageal reflux disease, peptic ulcer disease, and chronic liver disease. However, significant unmet medical needs remain for many major GI disorders. Ventrus Biosciences is positioned to address three of the top 10 GI disorders in the United States: anal fissure, fecal incontinence, and hemorrhoids. The combined patient population of these three disorders exceeds 26 million adults. In the market segments of fecal incontinence and anal fissure, the FDA has never approved a pharmaceutical treatment. In the market segment of hemorrhoids, the FDA has not approved a new pharmaceutical treatment within the last 35 years.

Partnering and licensing
Ventrus Biosciences is acquiring and developing technologies that leverage the company's strengths – a strong management team, renowned scientific advisers, and best-in-class development facilities. If you would like additional information about a partnership with Ventrus Biosciences, please contact Thomas Rowland, president and chief executive officer, at 720.528.4089 or at trowland@ventrusbio.com.

Submit a technology
Ventrus Biosciences actively works with entrepreneurs. We encourage submission of business plans/summaries. Please contact Thomas Rowland, president and chief executive officer, at 720.528.4089 or at trowland@ventrusbio.com.